Evercore ISI initiated coverage of DexCom (DXCM) with an In Line rating and $68 price target Though DexCom serves the “large and vastly underpenetrated” diabetes market, the firm’s In Line rating reflects its belief that product quality and manufacturing issues and competitive threats will continue to disrupt the company’s share gain opportunity through 2026, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: